ASP Isotopes executives and directors sold more than $2.5 million in shares during the month leading up to July 4, 2026. This selling activity follows the company’s stated goal of reaching $300 million in EBITDA by 2031. While some transactions covered tax obligations for vested awards, the high volume has drawn significant investor attention.
The company’s stock closed at $5.63 on July 2, 2026, trading near its 52-week low. ASP Isotopes reported a net loss of $7.1 million for the first quarter of 2026. Revenue for the same period totaled $4.2 million. These insider sales highlight a disconnect between executive actions and the firm's optimistic long-term financial targets.